VYNE Therapeutics Inc. (NASDAQ:VYNE) finished Friday with an addition of $0.01 to close at $0.15, an upside of 9.49 percent. An average of 637,040 shares of common stock have been traded in the last five days. There was a gain of $0.0228 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 400,735 shares traded, while the 50-day average volume stands at 269,134.
VYNE stock has decreased by -35.51% in the last month. The company shares reached their 1-month lowest point of $0.1107 on 12/23/22. With the stock rallying to its 52-week high on 01/04/22, shares of the company touched a low of $0.11 and a high of $1.18 in 52 weeks. It has reached a new high 2 times so far this year and lost -85.29% or -$0.8700 in price. In spite of this, the price is down -87.29% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
VYNE Therapeutics Inc. (VYNE) stock’s beta is 1.34. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.33, the price-to-book (PB) ratio at 0.22.
Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending September 29. Its gross profit as reported stood at $11.41 million compared to revenue of $14.76 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, VYNE Therapeutics Inc.’s return on assets was -42.60%.
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$9.46 million in the quarter, while revenues of -$8.48 million were grew 325.05%. The analyst consensus anticipated VYNE Therapeutics Inc.’s latest quarter earnings to come in at -$0.17 per share, but it turned out to be -$0.16, a 5.90% surprise. For the quarter, EBITDA amounted to -$9.16 million. At the end of the quarter ending September 29, VYNE Therapeutics Inc.’s stock balance sheet showed total liabilities of 6.84 million. Shareholders own equity worth $58.04 million.
From a technical analysis perspective, let’s take a brief look at VYNE Therapeutics Inc. (VYNE) price momentum. RSI 9-day as of the close on 30 December was 42.40%, suggesting the stock is Neutral, with historical volatility in this time frame at 125.07%.
As of today, VYNE’s price is $0.1364 +17.92% or $0.0228 from its 5-day moving average. VYNE is currently trading -33.60% lower than its 20-day SMA and -62.94% lower than its 100-day SMA. However, the stock’s current price level is -40.00% below the SMA50 and -73.91% below the SMA200.
The stochastic %K and %D were 31.24% and 25.98%, respectively, and the average true range (ATR) was 0.0189. With the 14-day stochastic at 39.58% and the average true range at 0.0188, the RSI (14) stands at 37.64%. The stock has reached 0.0021 on the 9-day MACD Oscillator while the 14-day reading was at -0.0093.